NinePointTwo Capital’s Acadia Pharmaceuticals ACAD Stock Holding History

NinePointTwo Capital’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-16,702	Closed	-$265K	–	258
2022 Q4	$265K	Buy	+16,702	New	+$261K	0.11%	48

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

NinePointTwo Capital's ACAD Position: Q1 2023 in Review

NinePointTwo Capital sold out of Acadia Pharmaceuticals (ACAD) in Q1 2023, closing a stake of 16,702 shares — an estimated $265K sold.

NinePointTwo Capital first reported a position in ACAD in Q4 2022 and held it in 1 quarter. The position peaked at $265K in Q4 2022. 233 funds tracked by Wall St. Rank hold ACAD as of Q1 2023.

NinePointTwo Capital reported no remaining Acadia Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
NinePointTwo Capital sold 16,702 Acadia Pharmaceuticals shares in Q1 2023, an estimated $265K.
NinePointTwo Capital first reported a position in Acadia Pharmaceuticals in Q4 2022 and held it in 1 quarter.
NinePointTwo Capital's Acadia Pharmaceuticals position peaked at $265K in Q4 2022.
233 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q1 2023.

Based on NinePointTwo Capital's 13F filing for Q1 2023, filed 15 May 2023.